eligibility_summary
Adults ≥18 with consent, ECOG 0–2, survival >3 mo, HGB ≥60 g/L, adequate organ function, contraception if applicable. Relapsed/refractory cohorts: B‑cell lymphoma (CD19/20/22/BAFF+, prior anti‑CD20 and anthracycline), T‑cell lymphoma (CD7+), B‑ALL (CD19/20/22/BAFF+), T‑ALL/LBL (CD7+), multiple myeloma (BCMA/CD19/GPRC5D+, ≥1 prior incl PI/IMiD), AML/MDS (CD7/19/47+). Exclude severe heart/lung disease, other active cancer, uncontrolled infection/autoimmunity/immunodeficiency, active HBV/HCV, HIV/syphilis, severe biologic allergy, active GVHD post allo‑HSCT, or other high‑risk conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase I/II, single-arm CAR-T therapy for relapsed/refractory hematologic malignancies. 1) Intervention and mechanism: Autologous, gene‑modified cellular immunotherapy (CAR-T cell infusions, constructs include CAR2219, CAR2019, CAR19, etc.). Mechanism: patient T cells are engineered to express chimeric antigen receptors that bind tumor surface antigens, triggering T‑cell activation, cytokine release, and targeted cytotoxic killing. 2) Targets (cells/pathways): Antigens by disease cohort—B-lineage: CD19, CD20, CD22, BAFF (B-cell survival axis) in B‑NHL and B‑ALL, T-lineage: CD7 in T‑ALL/LBL and T‑cell lymphoma, Myeloma: BCMA and/or CD19 and/or GPRC5D on malignant plasma cells, Myeloid tumors (AML/MDS): CD7 and/or CD19 and/or CD47 (“don’t‑eat‑me” axis). Targets malignant B cells, T cells, plasma cells, and myeloid blasts.